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background: Abnormal fetal testis development can result in disorders of sex development (DSDs) and predispose to later testicular
dysgenesis syndrome (TDS) disorders such as testicular germ cell tumours. Studies of human fetal testis development are hampered by
the lack of appropriate model, and intervention systems. We hypothesized that human fetal testis xenografts can recapitulate normal
development.
methods: Human fetal testes (at 9 weeks, n ¼ 4 and 14–18 weeks gestation, n ¼ 6) were xenografted into male nude mice for 6 weeks,
with or without hCG treatment of the host, and evaluated for normal cellular development and function using immunohistochemistry, triple
immunoﬂuorescence and testosterone assay. The differentiation and proliferation status of germ cells within xenografts was quantiﬁed and
compared with age-matched controls.
results: Xenografts showed .75% survival with normal morphology. In the ﬁrst-trimester xenografts seminiferous cord formation was
initiated and in ﬁrst- and second-trimester grafts normal functional development of Sertoli, Leydig and peritubular myoid cells was demon-
strated using cell-speciﬁc protein markers. Grafts produced testosterone when hosts were treated with hCG (P ¼ 0.004 versus control).
Proliferation of germ cells and differentiation from gonocytes (OCT4
+) into pre-spermatogonia (VASA
+) occurred in grafts and quantiﬁcation
showed this progressed comparably with age-matched ungrafted controls.
conclusions: Human fetal testis tissue xenografts demonstrate normal structure, function and development after xenografting,
including normal germ cell differentiation. This provides an in vivo system to study normal human fetal testis development and its susceptibility
to disruption by exogenous factors (e.g. environmental chemicals). This should provide mechanistic insight into the fetal origins of DSDs and
TDS disorders.
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Introduction
Formation of a testis from the indifferent gonad is orchestrated by the
SRY gene, resulting in differentiation of Sertoli cells (Wilhelm et al.,
2007). These then enclose the fetal germ cells (gonocytes) to form
seminiferous cords, starting at 7–9 weeks’ gestation (Wartenberg,
1981; Tilmann and Capel, 1999; Hanley et al., 2000; Gaskell et al.,
2004; Ostrer et al., 2007). Fetal Leydig cells then differentiate and
via hormone secretions, primarily testosterone, bring about bodywide
masculinization (Scott et al., 2009).
Disorders of sex development (DSDs) may result from failure of
normal gonadal development or subnormal androgen production/
action (Hughes, 2008). Such disorders can predispose to development
of testicular germ cell tumours (TGCTs) in young adulthood from pre-
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Meyts, 2006). CIS cells are thought to originate because of failure of
normal differentiation of fetal germ cells into prespermatogonia
(Rajpert-De Meyts, 2006), a process that encompasses fetal and early
post-natal life in humans and involves the loss of expression of pluripo-
tency factors (OCT4 and NANOG) and expression of proteins indica-
tive of differentiation (VASA and MAGE-A4) (Gaskell et al., 2004;
Anderson et al., 2007; Mitchell et al., 2008). TGCT may be the most
serious manifestation of a testicular dysgenesis syndrome (TDS),
which also includes some cases of undescended testis, hypospadias
and low sperm counts; these TDS disorders are all thought to result
from maldevelopment of the fetal testis (Skakkebaek et al., 2001).
Much of our understanding of normal and disrupted testicular devel-
opment derives from rodent models (Wilhelm et al., 2007; Gassei
et al., 2008), because only retrospective studies are usually possible
in patients with DSDs or TDS disorders, preventing identiﬁcation of
the mechanisms linking fetal testis maldevelopment to altered cell
development/function. However, there are major fundamental differ-
ences in the pace and duration of fetal testis development between
primates and rodents (Ehmcke et al., 2006), especially regarding
fetal germ cell differentiation (Mitchell et al., 2008). Its long duration,
in particular, limits the use of in vitro testis explants as an investigative
approach. Such differences may explain why rodents do not develop
TGCT equivalent to that in humans (Oosterhuis and Looijenga,
2005; Mitchell et al., 2008; Anderson et al., 2009).
Testicular xenografting has become increasingly utilized as a technique
in germ/stem cell biology, fertility preservation and the production of
transgenic sperm (Wistuba and Schlatt, 2002; Dobrinski, 2008; Ehmcke
and Schlatt, 2008; Schlatt et al.2 0 1 0 ). Xenografting of immature testis
tissue from several species, including the rhesus macaque, into a nude
mouse host results in full spermatogenesis within the grafted tissue
(Honaramooz et al., 2004; Rodriguez-Sosa and Dobrinski, 2009).
Previous reports of human testis xenografts show limited survival when
post-natal tissue is grafted (Geens et al., 2006; Schlatt et al., 2006)a n d
studies of fetal testis xenografts have been limited to descriptive reports
of small numbers of second-trimester grafts (Povlsen et al., 1974;
Skakkebaek et al., 1974; Yu et al., 2006). Therefore, the aim of the
present study wastoinvestigatethe suitabilityof human fetal testis xeno-
grafting as a technique to recapitulate normal fetal testis development,
including germ cell differentiation. Such a system would be invaluable
for mechanistic investigation of the origins of DSD and TDS disorders
such as CIS (TGCT).
Materials and Methods
Tissue collection
First-trimester (9 weeks, n ¼ 4) and second-trimester (14–18 weeks,
n ¼ 6)humanfetaltesteswereobtainedfollowingterminationofpregnancy.
Women gaveconsent in accordancewith national guidelines (Polkinghorne,
1989), and ethical approval was obtained from the Lothian Research Ethics
Committee. No terminations were related to fetal abnormalities. A small
portion of each testis was ﬁxed as a pre-graft control, while the remainder
was placed immediately into ice-cold media containing Liebowitz L-15
with glutamine, 10% fetal bovine serum, 1% penicillin/streptomycin and
1% non-essential amino acids (all Sigma, Poole, UK) for xenografting. Fetal
testis specimens were also obtained at gestational ages equivalent to the
end of the grafting period and ﬁxed as age-matched controls.
Xenografting procedure
Xenografting was performed following ethical approval from Lothian
Research Ethics Committee and animals were maintained in accordance
with UK Home Ofﬁce guidelines. Male CD1 nude mice (n ¼ 18, Charles
River UK, Margate, England) were anaesthetized by inhalation of isoﬂuor-
ane, castrated and small pieces (1 mm
3 approx.) of donor human testis
tissue were inserted subcutaneously under the dorsal skin using a 13G
cancer implant needle (Popper and Sons, NY, USA). Between three and
six testis grafts from a single fetus were inserted on either side of the
midline. Mice were housed individually and received analgesia (Rimadyl
LA, Pﬁzer, NY, USA) and antibiotics (Baytril, Bayer, Germany) in the drink-
ing water for 5 days post-surgery. After 7 days, mice with second-trimester
xenografts were randomly assigned to receive s.c. injections of either hCG
(n ¼ 6, 20 IU, three times a week, Pregnyl, Organon Laboratories,
Cambridge, UK) in 0.9% saline containing 1% fetal bovine serum, or the
vehicle. Grafts were retrieved after 6 weeks. Host mice were killed by cer-
vical dislocation and blood obtained by cardiac puncture for measurement
of testosterone. Seminal vesicles were removed and weighed, and xeno-
grafts were retrieved and weighed.
Tissue ﬁxation and processing
Pre-graft, xenograft and equivalent age-matched control tissues were ﬁxed
for 2 h in Bouins, transferred to 70% ethanol and then processed into par-
afﬁn blocks using standard procedures.
Immunohistochemistry
Antibodies, dilutions and requirement for antigen retrieval are shown in
Table I. Immunohistochemistry was performed with Tris-buffered saline
(TBS, 0.05 M Tris and 0.85% NaCl, pH 7.6) washes between each step
(Mitchell et al., 2008). Sections (5 mm) were subjected to heat-induced
antigen retrieval in 0.1 M citrate buffer (pH 6) and endogenous peroxidase
blocked with 3% (v/v) H2O2 in methanol for 30 min. Endogenous biotin
was blocked using an avidin/biotin blocking kit (Vector Laboratories,
Inc., Peterborough, UK), according to manufacturers’ instructions. Sec-
tions were incubated in appropriate normal serum diluted 1:5 with TBS
........................................................................................
Table I Antibodies and conditions used for
immunohistochemistry in xenograft study using human
fetal testis tissue in nude mice.
Antigen Source Species Dilution Retrieval
AMH Santa Cruz
a Goat 1:500 N
AR Santa Cruz
a Rabbit 1:200 Y
MAGE-A4 Gift
c Mouse 1:20 N
OCT 4 Santa Cruz
a Goat 1:50 Y
SOX9 Chemicon
e Rabbit 1:80 Y
SMA Sigma
f Mouse 1:5000 Y
3b-HSD Gift
d Rabbit 1:1000 N
VASA Abcam
b Rabbit 1:500 Y
All antibodies were raised against human peptide sequences. AMH, anti-Mullerian
hormone; AR, androgen receptor; SMA, smooth muscle actin; 3b-HSD,
3b-hydroxysteroid dehydrogenase.
aSanta Cruz Biotechnology, CA, USA.
bAbcam, Cambridge, UK.
cDr Guilio Spagnoli, University Hospital, Basel, Switzerland.
dProf. Ian Mason, The Queen’s Medical Research Institute, Edinburgh, UK.
eChemicon/Upstate/Linco.
fSigma, Poole, UK.
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were incubated overnight with primary antibody diluted in serum at 48C
in a humidiﬁed chamber and then incubated for 30 min with the appropri-
ate biotinylated secondary antibody, diluted in normal serum, followed by
30 min incubation with Streptavidin-horse-radish peroxidase (DAKO, Ely,
Cambridgeshire, UK) at 1:1000, diluted in TBS. Visualization was per-
formed using 3,3′-diaminobenzidine tetrahydrochloride (DAB, DAKO)
and sections were counterstained with haematoxylin before mounting in
Pertex mounting medium (CellPath plc, Hemel Hempstead, UK). Negative
controls were sections in which the primary antibody was replaced with
the appropriate normal serum. Images were captured as previously
described (Mitchell et al., 2008).
For double immunohistochemistry, the ﬁrst primary antibody was
detected using Streptavidin alkaline phosphatase (DAKO) at 1:400 for
30 min and visualized with 1 mg/ml Fast Blue (Sigma) in fast blue buffer,
until desired staining was achieved (typically 10–15 min). The second
primary antibody was then applied and subsequent steps were as
described above for single immunostaining.
Triple immunoﬂuorescence
Details of antibodies and detection reagents are shown in Table II. Antigen
retrieval, blocking and incubation with the ﬁrst primary antibody were per-
formed as described for immunohistochemistry, with phosphate-buffered
saline (PBS) replacing TBS. Sections were incubated with a peroxidise-
conjugated secondary antibody diluted in normal serum/PBS/BSA for
30 min and kept in the dark thereafter. Slides were then incubated with
labelled Tyramide diluted in buffer at 1:50 for 10 min before placing in
citrate buffer and microwaving on full power for 2.5 min and left to cool
for a further 30 min. The incubation of primary antibody, peroxidise-
conjugated secondary and Tyramide (with different ﬂuorescent labels),
was repeated for the second and third primary antibodies, with a
second microwave citrate retrieval prior to the third primary antibody.
Sections were counterstained with 4′,6-diamidino-2-phenylindole (DAPI,
Sigma) diluted 1:1000 in PBS for 10 min. Slides were mounted using Per-
maﬂuor (Immunotech, Marseille, France). Images were captured using an
LSM 510 Meta Confocal microscope (Carl Zeiss, Hertfordshire, UK).
Quantiﬁcation of germ cell differentiation
and proliferation
Quantiﬁcation of germ cell subpopulations and proliferation indices were
performed for the triple-stained sections. Images were obtained using an
Axiovert 200 M microscope with attached Axiocam HRc camera and
Axiovision 4.6 software (all Carl Zeiss). All germ cells within each
section were counted and quantiﬁed according to their protein expression
proﬁle and proliferation status using Adobe Photoshop 7.0 (Adobe,
San Jose, CA, USA).
Testosterone assay
Host serum testosterone levels were measured by competitive radio-
immunoassay using radiolabelled testosterone (I
125, MP Biomedicals,
UK) and a rabbit primary antibody (1:600 000, AMS Biotech, Abingdon,
UK). Residual I
125 was measured with a gamma counter (WIZARD
1470, Perkin Elmer, Turku, Finland) and testosterone levels were
expressed as ng/ml.
Statistics
Statistical analysis was performed using Graphpad Prism 5 software
(La Jolla, CA, USA). Multiple groups were analysed using one-way analysis
of variance, while comparisons between pre-graft control and xenografted
material taken from the same fetus were compared using a paired t-test.
Statistical signiﬁcance was set at P , 0.05.
Results
Retrieval rates, growth and gross
morphology of human fetal testis xenografts
Surviving grafts were easily identiﬁable as a distinct mass on the under
surface of the dorsal skin. Retrieval rates were similar with 9/12 (75%)
ﬁrst-trimester and 50/65 (77%) second-trimester grafts recovered.
Most xenografts had grown from a diameter of  1–3mm
3 and
their weights ranged from 0.1 to 5.2 mg (mean 2.1 mg). Grafts were
enclosed by a capsule, separating the testis material from the sur-
rounding s.c. tissue of the host (Fig. 1A). The recovered grafts exhib-
ited normal gross appearance, with recognizable seminiferous cords
(containing Sertoli cells and germ cells) surrounded by an interstitium
containing Leydig cells in 9/9 (100%) of ﬁrst-trimester and 47/50
(94%) of second-trimester grafts (Fig. 1A).
Formation of seminiferous cords in
ﬁrst-trimester human fetal testis xenografts
At the time of grafting, seminiferous cords had not fully formed in ﬁrst
trimester testes, but cords formed during the grafting period and
exhibited a normal appearance (Fig. 1A). At grafting, Sertoli cells
(identiﬁed by expression of SOX9) had aggregated but not formed
obvious cords and many of the germ cells (identiﬁed by expression
of OCT4) were still located in areas devoid of Sertoli cells (Fig. 1B).
After grafting, Sertoli cells had enclosed the germ cells in seminiferous
cords surrounded by a layer of cells expressing smooth muscle actin
(SMA; presumptive peritubular myoid cells), which was not evident
in pre-graft controls (Fig. 1C).
Functional development of Sertoli and
Leydig cells in ﬁrst-trimester human fetal
testis xenografts
Androgen receptor (AR) immunoexpression was not evident in ﬁrst
trimester pre-graft control testis tissue, but after grafting for 6
weeks AR expression was observed in peritubular myoid cells and
in some interstitial cells, a pattern comparable with equivalent age-
matched controls (Fig. 2). Anti-Mu ¨llerian hormone (AMH) was
........................................................................................
Table II Antibodies and conditions for triple
immunoﬂuorescence in xenograft study using human
fetal testis tissue in nude mice.
Antigen Dilution Secondary
antibody
Visualization
OCT4 1:150
aCAG-p
cTyr-Cy3 (10 min)
MAGE-A4 1:100
bCAM-p
dTyr-Cy5 (10 min)
Ki67 1:200
bCAM-p
eTyr Fluor (10 min)
aCAG-p, Chicken anti-goat peroxidase (Sigma, Poole, UK).
bCAM-p, Chicken anti-mouse peroxidase (Sigma, Poole, UK).
cTyr Cy3, Tyramide Cy3 (Perkin Elmer, MA, USA).
dTyr Cy5, Tyramide Cy5 (Perkin Elmer).
eTyr Fluor, Tyramide Fluorescien (Perkin Elmer).
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control and expression was maintained in the cytoplasm of presump-
tive Sertoli cells after grafting, and was similar in localization to equiv-
alent age-matched controls (Fig. 2).
Steroidogenesis and testosterone production
by human fetal testis xenografts
Differentiation and functional activation of Leydig cells was assessed in
the xenografts. In the absence of hCG treatment, Leydig cell cyto-
plasm was scanty compared with the conspicuous cytoplasm in
Leydig cells from second-trimester grafts of hCG-treated animals
(Fig. 3A). In vehicle-treated controls, the Leydig cells within grafts
were mostly immunonegative for 3b-hydroxysteroid dehydrogenase
(3b-HSD), but this enzyme was strongly expressed in Leydig cells
from hCG-exposed grafts, indicating induction of steroidogenesis
(Fig. 3A). Testosterone production was below the level of detection
in (untreated) hosts bearing ﬁrst-trimester xenografts, while low
levels were detected (mean 0.07+0.04 ng/ml) in vehicle-treated
hosts bearing second-trimester grafts. Treatment of hosts bearing
second-trimester xenografts with hCG resulted in nearly a 10-fold
increase (mean 0.68+0.23 ng/ml, P ¼ 0.004) in serum testosterone
levels (Fig. 3B). Seminal vesicle weight was also signiﬁcantly (3-fold)
increased in hCG-treated animals compared with vehicle-treated con-
trols (Fig. 3B).
Germ cell differentiation in human fetal
testis xenografts
The gonocyte pluripotency marker OCT4 was expressed in most
germ cells of ﬁrst trimester testes prior to grafting, while after grafting
some of the germ cells had ceased to express this protein, coincident
Figure 1 (A) Haematoxylin and eosin. Seminiferous cord formation in ﬁrst-trimester human fetal testis xenografts. Pre-graft control testes (left)
lacked completed seminiferous cord formation, while grafts had developed seminiferous cords with normal appearance (right). (B) Identiﬁcation
of cell types within newly formed seminiferous cords in ﬁrst-trimester human fetal testis xenografts (right) in comparison with pre-graft controls
(left) based on immunoexpression of SOX9/OCT4. Isolated OCT4
+ (brown) germ cells can be identiﬁed (arrowheads) in areas devoid of SOX9
(blue) expressing Sertoli cells in pre-graft controls, but after grafting all germ cells are enclosed within clearly deﬁned seminiferous cords. (C) The
cords are separated from the interstitial compartment by a basement membrane outlined by the expression of SMA, (arrows), while the pre-graft
control tissue is negative for SMA. Scale bar ¼ 50 mm. Negative controls are also shown (inset).
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into pre-spermatogonia, such as MAGE-A4 and VASA (Fig. 4A). The
latter were only rarely expressed in germ cells in ﬁrst trimester
testes prior to grafting. Similar results were obtained using second-
trimester grafts. These results suggested that germ cells differentiate
during the grafting period similar to that which occurs normally in
the intact testis. To establish if this was the case, quantiﬁcation of
the change in germ cell differentiation marker expression was
performed on sections co-stained for OCT4 and VASA (Fig. 4B).
The results conﬁrmed that the % of cells expressing OCT4 decreased
during the grafting period while the % of cells expressing VASA
increased. The% of cells expressing OCT4 after grafting was signiﬁ-
cantly reduced when compared with the pre-graft control tissue for
both ﬁrst and second trimester testes, while the % of cells expressing
VASA signiﬁcantly increased in the ﬁrst-trimester grafts, compared
with the pre-graft control. Further evidence for normal germ cell
differentiation after grafting is that the % of cells expressing OCT4
or VASA in xenografts was not signiﬁcantly different from that found
in equivalent age-matched controls (Fig. 4B). Comparable results
were also obtained when germ cells were co-stained for OCT4 and
MAGE-A4 (not shown).
Proliferation of cells within human fetal testis
xenografts
Development stage-speciﬁc germ cell proliferation was evaluated in
the human fetal testis xenografts by triple staining for OCT4,
MAGE-A4 and the proliferation marker Ki67. This demonstrated
that a proportion of all three subpopulations of germ cells
(OCT4
+/MAGE-A4
2, OCT4
+/MAGE-A4
+ and OCT4
2/MAGE-
A4
+) were proliferating (Fig. 5A). Quantiﬁcation of the proliferation
index (PI) for the different germ cell subpopulations showed that
OCT4
+/MAGE-A4
2 germ cells (i.e. undifferentiated) had the
highest PI, while the subpopulations that expressed MAGE-A4 (i.e. dif-
ferentiated) had a lower PI. This was the case for both ﬁrst and
second trimester testis grafts and was similarly evident in pre-graft
controls and equivalent age-matched controls (Fig. 5B). However,
there was a signiﬁcantly decreased PI in OCT4
+ cells from ﬁrst-
trimester grafts compared with the pre-graft control and equivalent
age-matched control, while in second trimester samples proliferation
of OCT4
+ germ cells was reduced in the equivalent age-matched
control compared with the pre-graft and grafted tissues. There
were no signiﬁcant differences in the PI for MAGE-A4
+ cells in
grafts when compared with pre-graft and equivalent age-matched
controls.
Discussion
The present study has demonstrated that human fetal testis develop-
ment can be recapitulated using the xenografting approach and that
overall testis (graft) growth and cellular proliferation/differentiation
appear to progress normally. Graft survival rates were excellent
(.75%) and the vast majority of retrieved grafts had normal testis
structure with seminiferous cords of normal appearance.
Our study provides the ﬁrst demonstration of ex situ seminiferous
cord formation in the human testis as we have shown that ﬁrst-
trimester human fetal testis xenografts can form normal seminiferous
cords, the timing of which matches that described previously for the
normal intact human fetal testis (Wartenberg, 1981; Hanley et al.,
2000; Ostrer et al., 2007). Xenografting of ﬁrst trimester fetal testes
thus has potential for investigating the mechanisms of normal human
fetal testis development, and may also be useful for studies that aim
Figure 2 Expression of AR and AMH in ﬁrst-trimester human fetal testis xenografts. Androgen receptor (AR, upper panels) is not expressed in the
pre-graft control, but is expressed in the grafts and equivalent age-matched controls. A negative control is also shown (inset). AMH (lower panels) is
expressed in ﬁrst trimester pre-graft controls and localized to Sertoli cells within the newly formed seminiferous cords after grafting and in an
equivalent age-matched control. Scale bar ¼ 50 mm.
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(dysgenesis). However, in order to establish validity of the xenografting
model for use in such studies, it was considered vital to ﬁrst determine
whether xenografts continue to develop normally from a structural,
functional and hormonal perspective. The present studies have
shown that testis structure is maintained throughout the ﬁrst and
second trimester and that expression of functional markers of
Sertoli (AMH), Leydig (3b-HSD) and peritubular myoid cells (SMA)
Figure 3 (A) Comparison of Leydig cell 3b-HSD expression (brown) in a second trimester pre-graft control (upper panel) and tissue from the same
testis after grafting into a vehicle-treated (lower panel; left) or hCG-treated mouse host (lower panel, middle). An age-matched control testis has also
been shown (lower panel, right). Note the presence of 3b-HSD expression in the hCG-exposed xenograft, similar to the age-matched control. Leydig
cell hypertrophy (*) was demonstrated in the hCG-treated grafts (lower middle panel, inset), compared with the vehicle-treated control graft (lower
left panel, inset) and the pre-graft control (upper panel, inset). Scale bar ¼ 50 mm. A negative control is shown (lower right panel, inset). (B) Tes-
tosterone production and seminal vesicle weights in untreated/vehicle-treated mice bearing human fetal testis xenografts from ﬁrst and second tri-
mester human fetal testes in comparison with hCG-treated mice bearing second-trimester grafts (second+hCG, n ¼ 3). Note that hCG
treatment results in a signiﬁcant increase in both testosterone (left panel) and seminal vesicle weight (right panel). Mean+SEM. **P , 0.01,
***P , 0.001, in comparison with vehicle-treated mice bearing second-trimester grafts.
2410 Mitchell et al.are comparable with those of equivalent age-matched controls. AR
and 3b-HSD were not expressed in ﬁrst trimester testes at 9 weeks
of gestation, but were expressed in the same testes 6 weeks after
xenografting, indicating that steroidogenesis is beginning to occur and
that the testes are becoming androgen responsive: SMA expression in
peritubular myoid cells is considered to be androgen-dependent
Figure 4 (A) Immunoexpression (brown) of OCT4 (top), VASA (middle) and MAGE-A4 (bottom) in germ cells in a ﬁrst trimester human testis
prior to grafting (Pre-graft control) and 6 weeks after grafting into a mouse host (graft). Note that after grafting, the proportion of germ cells expressing
OCT4 decreases as demonstrated by the presence of unstained germ cells (arrowhead), compared with the pre-graft control, whereas expression of
MAGE-A4 and VASA (arrows, inset) increase (neither are expressed in the pre-graft control). Scale bar ¼ 50 mm. (B) Quantiﬁcation of germ cell
differentiation in human fetal testis xenografts. The proportion of germ cells expressing OCT4 (red bars) or VASA (blue bars) in ﬁrst (upper
panels) and second (lower panels) trimester human fetal testes for pre-graft control, grafts and equivalent non-grafted controls. Values are
Mean+SEM for n ¼ 3 fetuses. *P , 0.05, **P , 0.01, ns, not signiﬁcant.
Xenografting of human fetal testis tissue 2411(Schlatt et al., 1993). In addition to these changes, weak expression of
AMH in ﬁrst trimester testes became stronger within the Sertoli cells
after xenografting. The change in expression patterns of AR, 3b-HSD
and AMH in testis xenografts is comparable with that described
previously for the human fetal testis between 7–9 and 14 weeks of
gestation (Gaskell et al., 2004).
Production of androgens is crucial for other aspects of testis devel-
opment such as Sertoli cell proliferation (Scott et al., 2007, 2008), as
Figure 5 (A) Proliferation (Ki67, green) of germ cell subpopulations in a second trimester human fetal testis xenograft based on
co-immunoexpression with either OCT4 (red), or MAGE-A4 (blue). Examples of proliferating germ cells expressing OCT4
+/MAGE-A4
2 (white
arrows), OCT4
+/MAGE-A4
+ (white arrowheads) and OCT4
2/MAGE-A4
+ (green arrows) can be seen. Many of the OCT4
2/MAGE-A4
+ popu-
lation are not proliferating (asterisk). The cells stained for Ki67 that are negative for OCT4 and MAGE-A4 represent proliferating Sertoli cells (orange
arrowhead). (B) Quantiﬁcation of the proportion of OCT4
+ (red bars) or MAGE-A4
+ (blue bars) germ cells that are proliferating in ﬁrst (upper
panels) and second (lower panels) trimester human fetal testes for pre-graft control, grafts (vehicle or hCG treated) and equivalent non-grafted con-
trols. Note the higher proliferation rate of OCT4
+ germ cells compared with MAGE-A4
+ cells. Values are Mean+SEM for n ¼ 3 fetuses. *P , 0.05.
2412 Mitchell et al.well as for masculinization of the reproductive organs (Auchus, 2004;
Scott et al., 2009). Our studies used measurement of serum testoster-
one and seminal vesicle weight in the host animal to determine the
steroidogenic function of the xenografts and showed that second-
trimester xenografts are capable of producing testosterone and that
this could be signiﬁcantly increased by hCG treatment. However, ﬁrst-
trimester xenografts did not produce detectable levels of testosterone
in host serum, which may be related to the relatively small size and
number of grafts in each host, or may be a result of age-related differ-
ences in the responsiveness of human grafts to host mouse LH, as has
been described in Rhesus monkey testis xenografts (Rathi et al., 2008).
We anticipate that hCG treatment of host mice carrying ﬁrst-trimester
human fetal testis xenografts would result in the production of detect-
able levels of testosterone.
Previous studies have demonstrated that germ cells are present in
second-trimester human fetal testis xenografts, but the identity and
differentiation of these cells was not demonstrated (Povlsen et al.,
1974; Skakkebaek et al., 1974; Yu et al., 2006). The present study
has shown that germ cell differentiation from gonocyte (OCT4
+/
MAGE-A4
2/VASA
2) to pre-spermatogonium (OCT4
2/
MAGE-A4
+/VASA
+), a process that normally takes place during
fetal and early post-natal life in the human, occurred normally in xeno-
grafts and was comparable with that of equivalent age-matched con-
trols (Gaskell et al., 2004; Anderson et al., 2007; Mitchell et al.,
2008). One minor exception was that OCT4
+ germ cells in the ﬁrst
trimester xenografts had a signiﬁcantly lower PI than did the pre-graft
or equivalent age-matched controls, and this could artifactually affect
the proportion of germ cells expressing OCT4 in the xenografts.
However, this could not account for the emergence of differentiated
(VASA
+ or MAGE-A4
+) germ cells in ﬁrst-trimester grafts compared
with pre-graft controls (most of which had no VASA or MAGE-A4
expressing cells prior to grafting) or for the increase in proportion
of differentiated germ cells in the second-trimester grafts. Taken
together these results indicate that germ cell differentiation occurs
in the xenografts and that this is broadly comparable with the
normal situation in vivo.
Having established xenografting as a suitable model for human fetal
testis seminiferous cord formation and germ cell differentiation, we
propose that it may be especially useful for studies investigating the
origins of DSDs and TDS in humans. DSDs often result from
genetic abnormalities involving the sex chromosomes or genes
involved in gonad development (Hughes et al., 2006). Genetic manipu-
lation of testis tissue or isolated cells prior to grafting has been shown
to be possible in studies that introduced the b-galactosidase gene into
bovine testis tissue that was subsequently xenografted (Oatley et al.,
2004). The xenografting technique may be modiﬁed to introduce
genes that either promote or disrupt normal cord formation and
testis development in human fetal testis xenografts and thus provide
an in vivo model of these conditions. DSDs may also result from
impaired androgen production or action. Several environmental
chemicals, such as certain phthalate esters, have been shown to
inhibit testosterone production by the fetal rat testis and to result in
a TDS-like phenotype in male offspring, but it remains unclear
whether these chemicals can exert similar effects in the human
(Scott et al., 2009). For example, in vitro studies with ﬁrst and second-
trimester human fetal testis explants have shown no inhibition of tes-
tosterone production by either of two different phthalates (Hallmark
et al., 2007; Lambrot et al., 2009), whereas in vivo studies have pro-
vided (indirect) evidence that such phthalates might impair androgen
production (Swan et al., 2005). The present results show that testis
xenografting would be a relevant approach via which to investigate
the effects of these chemicals on the development of the seminiferous
cords, germ cell development and steroidogenesis by the human fetal
testis under conditions in which normal cell development and function
appears to be occurring. Investigating the effects of phthalate esters in
this system may help to resolve the uncertainty about whether these
chemicals affect steroidogenesis (or other functions) of the fetal
human testis (Scott et al., 2009).
In conclusion, we have demonstrated for the ﬁrst time that human
fetal testis xenografts are a comparable in vivo ex situ model of normal
seminiferous cord formation, germ cell development and testosterone
production. Germ cells within xenografts differentiate from gonocytes
into pre-spermatogonia and proliferate in a manner similar to that in
normal age-matched control testes. In addition, grafts are capable of
producing testosterone, and an increase from basal levels can be
induced by hCG treatment of the host animal. We propose that
this system can be used to dissect the cellular mechanisms that under-
pin normal human fetal testis development, the disruption of which
can lead to common male reproductive disorders: these mechanisms
are otherwise inaccessible for study in situ and may be compromised
when studied in vitro. Genetic disruption of the initial stages of testis
development or manipulation of testosterone production by proposed
endocrine disruptors, using the xenograft approach, may be useful for
studies relating to DSD or the development of TDS and TGCT.
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